Earnings Releases·Nov 10, 2026, 7:06 AM ET

Cullinan Therapeutics — Third Quarter 2026 Earnings Summary

Cash and investments declined to $313.8 million as of September 30, 2026, from $439.0 million at year-end 2025, with a net loss of $49.4 million for the quarter compared to $50.6 million in the prior year period.
The company projects its current cash resources will sustain operations into 2029, supported by reduced operating expenses of $163.6 million for the first nine months versus $186.4 million in the prior year.
Significant regulatory and clinical milestones include the initiation of a registrational Phase 2 study for CLN-049 in AML, the initiation of a global Phase 1/2 study for Velinotamig in ITP and wAIHA, and the submission of an NDA for zipalertinib combination therapy in first-line NSCLC.
The Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint at interim analysis, and the company remains eligible for up to $130 million in regulatory milestone payments upon U.S. approvals for zipalertinib.